54% of Top-Selling Medicare Drugs Rated as Low-Benefit, Study Finds.

HEALTH policy; EVALUATION of medical care; DRUG approval; HEALTH services accessibility; LEGAL status of sales personnel; MEDICAL care costs; PUBLIC health; TREATMENT effectiveness; NATIONAL health services; CLINICAL medicine; MEDICAL prescriptions; MEDICARE; DOSAGE forms of drugs

The article reveals that 54% of top-selling brand-name Medicare drugs are rated as low-benefit, according to findings of a study from the Brigham and Women's Hospital and Harvard Medical School. The study found the ineligibility of top-selling Medicare drugs with limited added benefits for price negotiation due to restrictions set by the Inflation Reduction Act of 2022